Recruiting
Phase 1
Phase 2

Inefficiencies in irAE Detection

Sponsor:

Brigham and Women's Hospital

Code:

NCT06789601

Conditions

Malignancy

Immune Related Adverse Events

Eligibility Criteria

Sex: All

Age: 0+

Healthy Volunteers: Not accepted

Interventions

Informatics system for eligibility monitoring

Standard eligibility monitoring

Study Details

Brief summary:

Immunotherapies have improved cancer outcomes, but have a unique profile of immune-related adverse events (irAEs). Biorepositories have been established to collect data and samples to help improve our understanding of irAEs, however identifying patients who are eligible for these biorepositories in a timely fashion can be challenging. The goal of this study is to determine if an informatics system for automated irAE detection can improve registration to a prospective irAE biorepository (NCT04242095). The informatics system automatically "reads" participants' electronic health records (EHRs) and determines whether that patient may be experiencing an irAE. The main questions it aims to answer are:

  • Is it feasible to implement an informatics system for daily analysis of EHR data to detect irAEs?
  • Does the automated irAE detection system improve registration rates to an irAE biorepository at our institution following an eligible irAE?

Researchers will compare standard irAE monitoring to informatics-assisted irAE monitoring to see if using the informatics system increases the registration rate and improves data entry efficiency and quality.

Participants will:

  • Be randomly assigned to standard monitoring or informatics-assisted monitoring for irAE detection.
  • Have their EHR reviewed to collect demographic, medical, and cancer treatment history.
  • Be monitored for irAEs through daily automated analysis of their EHR data for up to 12 months or until registration in the biorepository.

Conditions

Malignancy

Immune Related Adverse Events

Study ID

NCT06789601

Start date

Jun 17, 2025

Status verified date

Jun, 2025

Completion date

Aug 31, 2027

Anticipated

Primary completion date

Aug 31, 2027

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 0+

Healthy Volunteers: Not accepted

Inclusion Criteria:

  • Received or receiving a regimen containing one or more immuno-oncology therapeutics

Study Design

Enrollment

100 participants

Anticipated

Allocation

Randomized

Intervention Model

Parallel Assignment

Primary purpose

Other

Interventions and Outcome Measures

Arms

other: Standard monitoring

Standard irAE monitoring for an eligible registration event.

experimental: Informatics-assisted monitoring

Informatics-assisted monitoring plus standard monitoring

Interventions

Informatics system for eligibility monitoring

A daily automated data query of eligible subjects will collect EHR data, and our informatics system will be run on these data behind our institution's secure firewall. The daily list of subjects identified by the informatics system as having a new irAE will be accessed by the Alliance irAE biorespository study team at Dana-Farber/Brigham Cancer Center for review.

Standard eligibility monitoring

Reporting of an eligible event to the biorepository study staff by the treating clinician and EHR review by the study staff.

Primary outcome measure

  • Feasibility [ Time Frame: 2 months ]
  • Registration [ Time Frame: 12 months ]

Central Contacts and Locations

Central contacts

Locations

Brigham and Women's Hospital

Recruiting

Boston, Massachusetts, United States, 02115

Contacts

Dana-Farber Cancer Institute

Recruiting

Boston, Massachusetts, United States, 02115

Contacts

More Information

Sponsor

Brigham and Women's Hospital

Last update posted

Jun 19, 2025

Last verified

Jun, 2025

Keywords

  • malignancy
  • adverse drug event
  • health informatics
  • natural language processing

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by Brigham and Women's Hospital on 2025-06-19.